The AKITA^® JET inhalation system

The AKITA^® JET inhalation system, combined with the latest jet nebulizer from PARI, provides optimal electronically-controlled inhalation of medication using Activaero's FAVORITE technology. The result sets the following standards:

Exceptional efficiency for a jet nebulizer [more]

Better lung dose reproducibility [more]
Precise "Drug Targeting" [more]

^{The AKITA JET inhalation system (HA-Projekt-Nr.: 144/08-06) has been supported by the state of Hess and their innovation promotion program, financed by LOEWE - Landes-Offensive zur Entwicklung Wissenschaftlich-ökonomischer Exzellenz, Förderlinie 3: KMU-Verbundvorhaben.}

AKITA^® JET - Exceptional efficiency for a jet nebulizer

Compared to conventional inhalation systems, AKITA^® JET allows for a significantly higher drug deposition in the lungs even with average dosing. This creates two possibilities:

Equivalent dosing can achieve a higher drug deposition in the lungs and a reduction of approximately 50% in drug investment.

Targeted dosing therapy can achieve a lung dose of three to five times higher than normal as compared to Dry Powder Inhalers (DPIs) and conventional nebulizers.

AKITA^® JET deposits around 75% of the dose measured at the mouthpiece into the lungs. These results can be seen in a number of in-vitro and in-vivo studies using Fluticasone.

: In vitro study with Fluticasone: Drug concentration at the mouthpiece and lung deposition measured using different inhalation systems.

^{Reference: Müllinger et al. 2008: Drug Output of Inhalers is not a Predictor of Lung Dose, Inhaled Drug Delivery Conference, 12-13 Nov 2008, Sofitel St. James London.}

These data indicates an excellent drug use efficiency, as well as a low throat deposition - this means, a high pulmonary dosage can be achieved without increasing the potential for side effects.

AKITA^® JET - Better lung dose reproducibility

AKITA^® JET has several advantages, particularly for drugs with a narrow therapeutic window and a high risk of side effects, e.g. antibiotics. The inhaled lung dosage can be easily reproduced with low variability. Data from a clinical study using Tobramycin shows that AKITA^® JET has significant potential in saving even the most expensive medications.

: Inhalation of Tobramycin in a homogeneous collective of 12 healthy volunteers, detected scinitigraphic means

^{Reference: Brandt et al. 2006; Reduction of Drug-Dose and Therapy-Costs in High-Dose Tobramycin-Inhalation, Journal of Cystic Fibrosis 2006; 5: Suppl 1: 86 June 2006.}

AKITA^® JET - Precise "Drug Targeting"

For the very first time, precise pulmonary "Drug Targeting" is now possible for inhalation therapy in combination with AKITA^® JET - depending on the drug and therapeutic goal, the location of drug deposition can easily be defined and adjusted.

: "Drug Targeting" to pre-defined regions in the lungs via controlled regulation of aerosolized drugs and air boluses.

The AKITA^® JET inhalation system fulfils the exact requirements needed in order to deliver the maximum amount of drug aerosol to the lower airways. Flow and volume-controlled inhalation with clearly defined drug patterns ("Drug Targeting") shows a clear superiority in peripheral alveolar deposition compared to conventional nebulizers and DPIs.

: Scintigraphic image of lung deposition in the alveoli of 10 COPD patients after inhalation of radioactive marked, mono-dispersed Fe3O4 particles with a flow rate of 200 cm³/s.

^{Reference: Sommerer et al. 2002; A Strategy to Optimize Peripheral Lung Deposition in Patients with Emphysema. Abstracts of the RDD Conference, Respiratory Drug Delivery, Arizona, USA 2002.}

[top]